AI ‘smart agents’ underutilized in fight against healthcare fraud

Stopping fraud before it’s perpetrated, cutting illicit payments and reducing hours spent by staff on such cases : These are three of the top four benefits healthcare administrators feel AI “smart agents” could deliver to their operations.

Stated another way, only one of the top four benefits healthcare admins would expect from an AI smart agent didn’t involve fraud, waste or abuse.

That’s according to a survey conducted by the online media channel PYMNTS in collaboration with Mastercard’s AI company Brighterion.

In an April 15 post summarizing the results, PYMNTS defines smart-agent technology as a form of AI that “can be assigned to multiple entities within a system and offer highly personalized decisioning capabilities.”

In its new survey, the company further found that more than a third of healthcare managers are at least “very interested” in implementing smart agent-based AI, while 13% are “extremely interested.”

The authors of the report note that, in various other industries, machine learning and artificial intelligence “have yielded powerful tools to manage such complex matters” as fighting fraud, waste and abuse. “Yet these advanced computational systems have a long way to go in healthcare administration.”

Only 4.3% of the healthcare sector currently use AI, according to PYMNTS’ latest research. By comparison, close to 10% of financial institutions have adopted the technology.

AI applications stand to save billions in healthcare administration annually, the authors assert.

“Better fraud detection also reduces false positives, erroneous judgments that block legitimate transactions,” they add. “A system that effectively stops fraudulent transactions is better at letting good ones through, and institutions that adopt AI-based fraud detection platforms reduce instances of false positives by more than tenfold.”

Click here to read an earlier and more detailed summary of the same survey report. Click here to download the full report (contact info required).

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.